David Marks, MD, PhD, from the University Hospitals Bristol NHS Foundation Trust, Bristol, UK, provides an overview of the randomized Phase III clinical trial UKALL14 for newly diagnosed acute lymphocytic leukemia (ALL) patients. Two of the main questions the trial seeks to answer is whether rituximab improves survival of B-cell ALL, and whether nelarabine improves survival of T-cell ALL. In terms of enrollment, the trial has accrued 600 of 720 patients, and should be finalized by the end of 2016. The trial also assesses the role of transplant in the treatment of ALL, particularly in older patients, with the intent to reduce the intensity of the transplant. Dr Marks also talks about how the field is changing in regard to relapsed/refractory ALL, with 3 new targeted-drugs (inotuzumab, blinatumomab and CAR T-cells). Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.